The effects of rutin flavonoid supplement on glycemic status, lipid profile, atherogenic index of plasma, brain-derived neurotrophic factor (BDNF), some serum inflammatory, and oxidative stress factors in patients with type 2 diabetes mellitus: A double-blind, placebo-controlled trial.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

This study aimed to investigate the effects of rutin flavonoid in type 2 diabetes mellitus (T2DM) patients.

Who Took Part

The study group was 50 patients.

At the beginning and at the end of the study, metabolic parameters including fasting blood glucose (FBG), insulin, glycosylated hemoglobin (HbA1c), homeostasis model assessment of insulin resistance (HOMO-IR), quantitative insulin sensitivity check index (QUICKI), homeostasis model assessment of β-cell function (HOMA-β), triglyceride (TG), total cholesterol (CHOL), high-density and low-density lipoprotein cholesterol (HDL-c and LDL-c), and atherogenic index of plasma (AIP), inflammatory and oxidative stress markers such as interleukin 6 (IL-6), total antioxidant capacity (TAC), and malondialdehyde (MDA) and brain-derived neurotrophic factor (BDNF) were assessed.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received Copper (Supplement).

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Brain-Derived Neurotrophic Factor, Glycated Hemoglobin, Insulin Resistance, Flavonoids, Rutin and Cholesterol, LDL.

The authors tagged it with the keywords BDNF, inflammation, metabolic parameters, oxidative stress and type 2 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 50 patients.

The publication is from 2023 (Phytotherapy research : PTR), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.